This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Mohamed Hachicha, Ph.D. Joins NexMed, Inc. As Vice President-Research And Development For NexMed, USA

NexMed, Inc. (Nasdaq: NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT ® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, announced today that Mohamed Hachicha, Ph.D., has been appointed to the position of Vice President, Research and Development for NexMed USA, effective immediately.

Dr. Hachicha brings to NexMed 15 years of experience in the pharmaceutical and biotechnology industries. Prior to joining NexMed, from 2005 to 2010, Dr. Hachicha served as Senior Principal Scientist in the Pharmacology and Drug Discovery Department at Forest Laboratories, where, among other things, he was responsible for managing and coordinating two of the company’s discovery research programs. From 1999 to 2005, he was Principal Investigator in the Molecular Pharmacology Department at Purdue Pharma, L.P., where he managed and coordinated the company’s multi-disciplinary discovery research program. Dr. Hachicha began his career as a Research Scientist in the Discovery Department at Pharmacopeia, Inc., and prior, conducted post doctorate research focused on inflammatory diseases at Harvard Medical School, where he authored key publications in the field of lipoxins.

Dr. Hachicha received his B.S. degree in Biochemistry from the University of Algiers, Algeria, and both his M.Sc. and Ph.D. in Immunology from Laval University, Canada. His technical expertise is in both in-vitro and in-vivo pharmacology. He is the recipient of many industry awards and has authored or co-authored a number of articles in peer-reviewed journals.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, noted, “Dr. Hachicha’s extensive experience and proven success in the field of drug development, from target identification and validation to the selection of clinical development targets, made him the best candidate for the key role of Vice President, Research and Development for NexMed USA and we are delighted to welcome him to the Company. Dr. Hachicha’s expertise will be instrumental as we move ahead with our strategy to maximize the possibilities for the NexACT technology.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs